BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1818300)

  • 1. Tumor necrosis factor alpha: a costimulator for cytotoxic cell differentiation.
    Chouaib S
    Nouv Rev Fr Hematol (1978); 1991; 33(6):471-5. PubMed ID: 1818300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for tumor necrosis factor-alpha involvement in the optimal induction of class I allospecific cytotoxic T cells.
    Robinet E; Branellec D; Termijtelen AM; Blay JY; Gay F; Chouaib S
    J Immunol; 1990 Jun; 144(12):4555-61. PubMed ID: 2161875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Involvement of tumor necrosis factor in the generation of LAK killer cells].
    Chouaib S; Blay JY
    Pathol Biol (Paris); 1990 Jan; 38(1):47-52. PubMed ID: 2308780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB; Gutterman JU; Grimm EA
    Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of cyclic adenosine monophosphate in the interleukin 4 inhibitory effect on interleukin 2-induced lymphokine-activated killer generation.
    Blay JY; Branellec D; Robinet E; Dugas B; Gay F; Chouaïb S
    J Clin Invest; 1990 Jun; 85(6):1909-13. PubMed ID: 2161432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Functional interaction between the tumor necrosis factor and interleukin 2 during induction of lymphokine activated killer cytotoxic activity].
    Blay JY; Bertoglio J; Gay F; Fradelizi D; Chouaib S
    C R Acad Sci III; 1988; 307(2):47-51. PubMed ID: 3138005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional interactions of IL2 and TNF in the differentiation of LGL into LAK effectors.
    Blay JY; Bertoglio J; Fradelizi D; Chouaib S
    Int J Cancer; 1989 Oct; 44(4):598-604. PubMed ID: 2793231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
    Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
    Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12.
    Cesano A; Visonneau S; Clark SC; Santoli D
    J Immunol; 1993 Sep; 151(6):2943-57. PubMed ID: 8104216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNF-alpha potentiation of the lymphokine-activated killer response of murine thymus cells.
    Ujházy P; Maccubbin D; Eppolito C; Mihich E; Ehrke MJ
    Lymphokine Cytokine Res; 1994 Apr; 13(2):99-106. PubMed ID: 8061121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional interactions between interleukin-4, interleukin-2, and tumor necrosis factor-alpha for lymphokine-activated killer cell generation.
    Blay JY; Branellec D; Robinet E; Gay F; Chouaib S
    J Clin Lab Anal; 1990; 4(1):54-8. PubMed ID: 2313467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
    Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
    Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
    Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
    Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-4 differentially regulates interleukin-2-mediated and CD2-mediated induction of human lymphokine-activated killer effectors.
    Robinet E; Kamoun M; Farace F; Chouaib S
    Eur J Immunol; 1992 Nov; 22(11):2861-5. PubMed ID: 1358624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures.
    Spits H; Yssel H; Paliard X; Kastelein R; Figdor C; de Vries JE
    J Immunol; 1988 Jul; 141(1):29-36. PubMed ID: 2454260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
    Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
    J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TGF beta down-regulates TLiSA1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells.
    Jin B; Scott JL; Vadas MA; Burns GF
    Immunology; 1989 Apr; 66(4):570-6. PubMed ID: 2541074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.